Avigen (Biotechnology) Overview
- Year Founded
-
1992
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$42.9M
Avigen (Biotechnology) General Information
Description
Operator of a development stage biopharmaceutical company intended to focus on smart drug development and value-creating partnerships. The company's focus lies in the development of gene therapy products, based on its AAV (adeno-associated virus) delivery platform technology, gene delivery products, which are designed for direct administration to patients in order to achieve expression of therapeutic proteins within the body and product development programs in hemophilia and Parkinson's diseases as well.
Contact Information
Corporate Office
- 1301 Harbor Bay Parkway
- Alameda, CA 94502
- United States
Corporate Office
- 1301 Harbor Bay Parkway
- Alameda, CA 94502
- United States
Avigen (Biotechnology) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 18-Dec-2009 | $42.9M | Completed | Generating Revenue | ||
| 5. Buyout/LBO | 15-Jan-2009 | Cancelled | Generating Revenue | |||
| 4. PIPE | 25-May-2006 | Completed | Generating Revenue | |||
| 3. PIPE | 12-Feb-2001 | Completed | Generating Revenue | |||
| 2. IPO | 22-May-1996 | $20M | $20M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Avigen (Biotechnology) Patents
Avigen (Biotechnology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2009017625-A1 | Treatment of depression, phychosis, and anxiety | Inactive | 27-Jul-2007 | ||
| WO-2008137012-A1 | Use of a glial attenuator to prevent amplified pain responses caused by glial priming | Inactive | 03-May-2007 | ||
| WO-2008133937-A2 | Compositions of tolperisone | Inactive | 26-Apr-2007 | ||
| WO-2008133937-A3 | Compositions of tolperisone | Inactive | 26-Apr-2007 | ||
| WO-2008103234-A1 | Process methods for fucoidan purification from seaweed extracts | Inactive | 23-Feb-2007 | C08B37/0063 |
Avigen (Biotechnology) Signals
Avigen (Biotechnology) Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BVF Partners | Hedge Fund | Minority | ||
| Bayer CropScience | Corporation | Minority | ||
| Federated Hermes (Pittsburgh) | Asset Manager | Minority | ||
| Johns Hopkins Technology Ventures | Accelerator/Incubator |
Avigen (Biotechnology) FAQs
-
When was Avigen (Biotechnology) founded?
Avigen (Biotechnology) was founded in 1992.
-
Where is Avigen (Biotechnology) headquartered?
Avigen (Biotechnology) is headquartered in Alameda, CA.
-
What is the size of Avigen (Biotechnology)?
Avigen (Biotechnology) has 12 total employees.
-
What industry is Avigen (Biotechnology) in?
Avigen (Biotechnology)’s primary industry is Biotechnology.
-
Is Avigen (Biotechnology) a private or public company?
Avigen (Biotechnology) is a Private company.
-
What is the current valuation of Avigen (Biotechnology)?
The current valuation of Avigen (Biotechnology) is .
-
What is Avigen (Biotechnology)’s current revenue?
The current revenue for Avigen (Biotechnology) is .
-
How much funding has Avigen (Biotechnology) raised over time?
Avigen (Biotechnology) has raised $56.1M.
-
Who are Avigen (Biotechnology)’s investors?
BVF Partners, Bayer CropScience, Federated Hermes (Pittsburgh), and Johns Hopkins Technology Ventures have invested in Avigen (Biotechnology).
-
When was Avigen (Biotechnology) acquired?
Avigen (Biotechnology) was acquired on 18-Dec-2009.
-
Who acquired Avigen (Biotechnology)?
Avigen (Biotechnology) was acquired by MediciNova.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process